Checkmate Pharmaceuticals Inc.

6.60-0.3100-4.49%Vol 63.77K1Y Perf -52.79%
Jun 14th, 2021 16:00 DELAYED
BID6.50 ASK7.09
Open6.90 Previous Close6.91
Pre-Market- After-Market-
 - -  - -%
Target Price
25.00 
Analyst Rating
— — 0.00
Potential %
278.79 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap142.73M 
Earnings Rating
Price Range Ratio 52W %
4.40 
Earnings Date
5th Jul 2021

Today's Price Range

6.526.94

52W Range

5.8423.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.08%
1 Month
-2.08%
3 Months
-55.38%
6 Months
-56.00%
1 Year
-52.79%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CMPI6.60-0.3100-4.49
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.75-0.6513.33
Q03 2020-0.40-0.84-110.00
Q02 2020--7.37-
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th Jul 2021
Estimated EPS Next Report-0.75
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume63.77K
Shares Outstanding21.63M
Trades Count756
Dollar Volume227.77K
Avg. Volume46.92K
Avg. Weekly Volume93.23K
Avg. Monthly Volume44.30K
Avg. Quarterly Volume63.41K

Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) stock closed at 6.6 per share at the end of the most recent trading day (a -4.49% change compared to the prior day closing price) with a volume of 63.77K shares and market capitalization of 142.73M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Checkmate Pharmaceuticals Inc. CEO is Barry A. Labinger.

The one-year performance of Checkmate Pharmaceuticals Inc. stock is -52.79%, while year-to-date (YTD) performance is -54.76%. CMPI stock has a five-year performance of %. Its 52-week range is between 5.84 and 23.1, which gives CMPI stock a 52-week price range ratio of 4.40%

Checkmate Pharmaceuticals Inc. currently has a PE ratio of -9.90, a price-to-book (PB) ratio of 1.33, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.32%, a ROC of -48.26% and a ROE of -48.15%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Checkmate Pharmaceuticals Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.75 for the next earnings report. Checkmate Pharmaceuticals Inc.’s next earnings report date is 05th Jul 2021.

The consensus rating of Wall Street analysts for Checkmate Pharmaceuticals Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Checkmate Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Checkmate Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Checkmate Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.61, ATR14 : 0.45, CCI20 : -30.38, Chaikin Money Flow : -0.36, MACD : -0.21, Money Flow Index : 54.99, ROC : 0.30, RSI : 41.10, STOCH (14,3) : 22.79, STOCH RSI : 0.04, UO : 28.98, Williams %R : -77.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Checkmate Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Checkmate Pharmaceuticals Inc.

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

CEO: Barry A. Labinger

Telephone: +1 617 682-3625

Address: 245 Main Street, Cambridge 02142, MA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits